Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies.
Hybridomas producing human monoclonal IgM antibodies (mAbs) against bacterial lipopolysaccharide (LPS) were generated by fusion of B lymphocytes from sensitized human spleen with heteromyeloma cells. The splenocytes were from patients undergoing splenectomy during staging for Hodgkin disease after vaccination with the J5 mutant of Escherichia coli, which is deficient in O antigenic side chains. This deficiency exposes the core oligosaccharide, common to LPS of all Gram-negative bacteria. The mAbs cross-reacted strongly with endotoxins from a wide range of unrelated species of Gram-negative bacteria. The mAbs also gave strong protection against LPS in the dermal Shwartzman reaction and against lethal Gram-negative bacteremia in mice. These findings indicate that monoclonal IgM against LPS endotoxin can neutralize its toxicity in vivo and might be valuable for treatment of patients with Gram-negative bacteremia. Analysis of one of the hybridoma clones, A6(H4C5), showed that the IgM mAb is directed against the covalently bound lipid A, which represents the most conservative and least variable structural element of LPS.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003429:Cross Reactions; D004731:Endotoxins / Q000633:toxicity; D006090:Gram-Negative Bacteria; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D007075:Immunoglobulin M / Q000008:administration & dosage*; D008070:Lipopolysaccharides / Q000276:immunology; D008297:Male; D051379:Mice; D018805:Sepsis / Q000517:prevention & control*; D014115:Toxemia / Q000517:prevention & control*
D000911:Antibodies, Monoclonal; D004731:Endotoxins; D007075:Immunoglobulin M; D008070:Lipopolysaccharides